No, high-risk HPV screening should NOT be performed for this 22-year-old woman.
For a healthy 22-year-old woman, high-risk HPV testing is explicitly not recommended and may cause more harm than benefit. The USPSTF issued a grade D recommendation against HPV testing in women younger than 30 years, indicating at least moderate certainty that the harms outweigh the benefits 1.
Why HPV Testing is Contraindicated in This Age Group
The rationale for avoiding HPV testing in women under 30 is straightforward:
- Extremely high prevalence of transient HPV infections: HPV infection is very common in young women but typically clears spontaneously without clinical significance 1
- Poor specificity: The high background rate of HPV positivity leads to excessive false-positive results that do not predict clinically important disease 2
- Unnecessary interventions: Positive HPV tests in this age group trigger colposcopies, biopsies, and potential treatments for lesions that have a high likelihood of spontaneous regression 1
- Psychological harm: Disclosing a sexually transmitted viral infection causes significant distress without providing meaningful clinical benefit 3
What Should Be Done Instead
At age 22, cervical cytology (Pap test) alone is the appropriate screening method, with screening beginning at age 21 regardless of sexual history 1. The screening interval should be every 3 years with cytology alone—not annually 1.
When HPV Testing Becomes Appropriate
HPV testing should only be considered starting at age 30 years 1, 3. At that age, HPV prevalence decreases substantially, and cotesting (cytology plus HPV) or primary HPV testing becomes clinically useful because:
- Lower HPV prevalence improves test specificity
- Persistent infections at this age are more likely to represent clinically significant disease
- Combined negative results allow safe extension of screening intervals to 5 years 1
Common Pitfall to Avoid
Do not order HPV testing as part of routine screening or "just to be thorough" in women under 30. This represents low-value care that generates anxiety and unnecessary follow-up procedures without improving cancer prevention outcomes.